Chapa Hector O, Venegas Gonzalo, Antonetti Alfred G, Van Duyne Charles P, Sandate Jeffrey, Bakker Ken
Women's Specialty Center, Dallas, Texas, USA.
J Reprod Med. 2009 Nov-Dec;54(11-12):678-84.
To evaluate the efficiency of in-office Thermachoice III (Ethicon, Somerville, New Jersey) endometrial ablations in resolving menstrual abnormalities as well as dysmenorrhea at 12 months after the procedure.
This was a prospective, single arm, cohort study of women from an inner city, community based, physician group medical/ surgical clinic. Diagnostic hysteroscopy, dilation and curettage, and Thermachoice III endometrial ablation were performed under local analgesia.
At baseline, N = 148. At 12 months, 23 patients were lost to follow-up, leaving 125 for the evaluable cohort. The largest resulting patient category was amenorrhea, with 66.4% (83 of 125 evaluable), followed by hypomenorrhea at 31% (39 of 125 evaluable). Three patients (2.4%) were considered clinical failures. These 3 patients initially were designated as having hypomenorrhea at 3 months. Dysmenorrhea reduction was statistically significant (p < 0.05) at 6 months and 12 months as compared to baseline.
At 1 year after the procedure, the efficiency of in-office Thermachoice III was observed, with high amenorrhea rates as well as persistently decreased dysmenorrhea.
评估门诊使用Thermachoice III（美国新泽西州萨默维尔市Ethicon公司生产）进行子宫内膜消融术在解决术后12个月月经异常及痛经方面的效果。
这是一项针对来自市中心社区内科医生团队医疗/外科诊所女性患者的前瞻性单臂队列研究。在局部麻醉下进行诊断性宫腔镜检查、刮宫术及Thermachoice III子宫内膜消融术。
基线时，N = 148。12个月时，23例患者失访，剩余125例纳入可评估队列。最大的患者类别是闭经，占66.4%（125例可评估患者中的83例），其次是月经过少，占31%（125例可评估患者中的39例）。3例患者（2.4%）被视为临床失败。这3例患者最初在3个月时被判定为月经过少。与基线相比，痛经在6个月和12个月时减轻具有统计学意义（p < 0.05）。
术后1年，观察到门诊使用Thermachoice III的效果，闭经率高且痛经持续减轻。
